25I Stock Overview
ImmuPharma plc, empresa biofarmacéutica, descubre y desarrolla terapias basadas en péptidos.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ImmuPharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.022 |
| 52 Week High | UK£0.04 |
| 52 Week Low | UK£0.0002 |
| Beta | 1.47 |
| 1 Month Change | -22.41% |
| 3 Month Change | 125.00% |
| 1 Year Change | 221.43% |
| 3 Year Change | -77.18% |
| 5 Year Change | -78.57% |
| Change since IPO | -98.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| 25I | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 7.1% | -6.0% | -1.3% |
| 1Y | 221.4% | -31.5% | 4.1% |
Rentabilidad frente al sector: 25I superó al sector German Pharmaceuticals , que obtuvo un rendimiento del -25.6% el año pasado.
Rentabilidad vs. Mercado: 25I superó al mercado German, que obtuvo un rendimiento del 4.9% el año pasado.
Price Volatility
| 25I volatility | |
|---|---|
| 25I Average Weekly Movement | 2,631.8% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: 25Iha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: 25ILa volatilidad semanal ha pasado de 1862% a 3394% en el último año.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 13 | Tim McCarthy | https://www.immupharma.co.uk |
ImmuPharma plc, empresa biofarmacéutica, descubre y desarrolla terapias basadas en péptidos. Sus terapias peptídicas se utilizan en los campos de la autoinmunidad, la inflamación y los antiinfecciosos. El principal producto candidato de la empresa es el Lupuzor, un inmunomodulador de la autofagia, que se encuentra en ensayos clínicos de fase III para el tratamiento del lupus, una enfermedad inflamatoria crónica autoinmune.
ImmuPharma plc Fundamentals Summary
| 25I fundamental statistics | |
|---|---|
| Market cap | €10.71m |
| Earnings (TTM) | -€3.49m |
| Revenue (TTM) | €81.57k |
131.3x
P/S Ratio-3.1x
P/E RatioIs 25I overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 25I income statement (TTM) | |
|---|---|
| Revenue | UK£69.96k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£69.96k |
| Other Expenses | UK£3.06m |
| Earnings | -UK£2.99m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0072 |
| Gross Margin | 100.00% |
| Net Profit Margin | -4,275.37% |
| Debt/Equity Ratio | 0% |
How did 25I perform over the long term?
See historical performance and comparison